The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Onboard AI partners with Cedars-Sinai to scale responsible adoption of AI

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Onboard AI and Cedars-Sinai will collaborate to deploy an automated, AI-native governance platform that health systems can use to streamline and strengthen the evaluation, approval, and monitoring of AI solutions.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Regulatory News

ESMO publishes guidances on AI tools for clinicians, patients, and researchers
Says one author: “We think there should be some degree of human oversight, otherwise, they can go completely rogue and nobody notices.”

The European Society For Medical Oncology has formally weighed in on a question that U.S. medical groups have been chipping away at as well: How can we guarantee safe and effective use of artificial intelligence in oncology?
By Sara Willa Ernst
Drugs & Targets

Université Paris-Saclay, Owkin partner to use AI co-pilot for biology research

Xavier Apolinarski (left), vice president of innovation at Université Paris-Saclay, and Eric Durand (right), chief research and technology officer at Owkin at the signing of the deal between Université Paris-Saclay and Owkin.Université Paris-Saclay and Owkin announce the signing of a memorandum of understanding to explore the potential of K Pro Free—Owkin’s AI co-pilot for biology—for use by Université Paris-Saclay.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account